

Deferoxamine

Essential medicine status

General description

Deferoxamine is an iron chelating agent used in the treatment of iron overload, acute iron toxicity and in the management of sickle cell disease.

INN

Deferoxamine

ATC codes

[V03AC01](#)

Medicine type

Chemical agent

EML status history

First added in 1979 ([TRS 641](#)) for [Harmful effects of drugs, medicaments or biological substances, not elsewhere classified](#)

Added in 2011 ([TRS 965](#)) for [Other specified sickle cell disorders or other haemoglobinopathies](#)

Added in 2023 ([TRS 1049](#)) for [Thalassaemias](#)

Wikipedia

[Deferoxamine](#)

DrugBank

[Deferoxamine](#)

Recommendations

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

[Harmful effects of drugs, medicaments or biological substances, not elsewhere classified](#)

Section

Medicines for haemoglobinopathies

- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

[Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias](#)